Vivos Therapeutics (VVOS) Cost of Revenue (2020 - 2026)

Vivos Therapeutics (VVOS) has 7 years of Cost of Revenue data on file, last reported at $2.1 million in Q1 2026.

• On a quarterly basis, Cost of Revenue rose 38.16% year-over-year to $2.1 million in Q1 2026; TTM through Mar 2026 was $7.5 million, a 23.8% increase from a year earlier, with the FY2025 full-year figure at $6.9 million, up 14.79% from the prior year.
• Cost of Revenue for Q1 2026 stood at $2.1 million, up from $836000.0 in the prior quarter.
• Over the last five years, Cost of Revenue for VVOS reached as high as $2.8 million in Q3 2025 and fell as low as $836000.0 in Q4 2025.
• Historically, Cost of Revenue has averaged $1.6 million across 5 years, with a median of $1.5 million in 2024.
• On a YoY basis, Cost of Revenue climbed as much as 86.5% in 2025 and fell as far as 47.78% in 2025.
• Year by year, Cost of Revenue stood at $1.6 million in 2022, then declined by 25.99% to $1.2 million in 2023, then jumped by 38.14% to $1.6 million in 2024, then sank by 47.78% to $836000.0 in 2025, then soared by 149.04% to $2.1 million in 2026.
• Per Business Quant data, the three most recent Cost of Revenue figures were $2.1 million in Q1 2026, $836000.0 in Q4 2025, and $2.8 million in Q3 2025.